文献速递免疫规划

抗SARS-CoV-2 mRNA疫苗接种后抗刺突IgG与中和抗体衰减的建模

Modeling of anti-spike IgG and neutralizing antibody waning after anti-SARS-CoV-2 mRNA vaccination.
PubMed 文献 · Vaccine · 2024-07-20

研究对1346名参与者的3059份血清样本检测抗S1 IgG和中和抗体,采用幂律模型模拟第二至第五剂疫苗接种后抗体滴度衰减,假设加强接种可显著降低抗体下降并延长维持时间。模型显示抗体衰减率在各年龄组间无显著差异,但第二剂后≤39岁组峰值滴度显著高于≥60岁组,此差异在第三、四剂后未观察到。

要点

  • 幂律模型可模拟mRNA疫苗接种后抗体滴度衰减并纳入预测区间。
  • 加强接种假设可显著降低抗S抗体和中和抗体下降,延长维持时间。
  • 第二剂后≤39岁组抗体峰值滴度显著高于≥60岁组,第三、四剂后未见此差异。

核心结论

  • 接种后抗体水平动力学建模被认为有助于理解mRNA疫苗受种者的免疫状态。

研究设计与样本

  • 研究检测了来自1346名参与者的3059份血清样本,量化抗S蛋白S1亚基IgG和中和抗体活性,采用幂律模型模拟第二、三、四、五剂疫苗接种后抗体滴度衰减。

主要发现

  • 模型假设加强接种可显著降低抗S抗体和中和抗体水平下降,使水平维持更长时间。
  • 各年龄组间抗体水平衰减率无显著差异。
  • 第二剂接种后≤39岁组抗体峰值滴度显著高于≥60岁组,第三和第四剂后未观察到这些差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

At present, mRNA-based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being administered on a global scale. While the efficacy of mRNA vaccines has been demonstrated, several unknowns remains. For example, as the number of booster vaccinations increases, there are uncertainties regarding how long effects of a vaccine will last and how much individual variability exists. In this study, to predict the duration of vaccine efficacy, we modeled the kinetics of antibody levels for each SARS-CoV-2 vaccination dose, incorporating predictive intervals to estimate the duration of vaccine efficacy and to account for variability among individuals. A total of 3,059 serum samples from 1,346 participants were assayed to quantify IgG antibodies specific for the S1 subunit of the S protein (anti-S1 IgG) and neutralizing antibody activities against SARS-CoV-2. A power law model was used to simulate the decay of antibody titers following vaccination, and models were constructed to assess antibody level kinetics after the second, third, fourth, and fifth vaccinations. The models assumed that booster vaccinations would significantly reduce the decline in anti-S antibody and neutralizing antibody levels, resulting in levels being maintained for a longer period. No significant differences in the decay rate of antibody levels were observed among age groups, yet the peak titers of antibody levels were significantly higher in the ≤ 39 age group than in the ≥ 60 age group following the second vaccination; these differences were not observed after the third and fourth vaccinations. The modeling of antibody level kinetics after vaccination is considered to be useful for understanding the immune status of mRNA vaccine recipients.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Sanada T, Honda T, Kohara M, et al. Modeling of anti-spike IgG and neutralizing antibody waning after anti-SARS-CoV-2 mRNA vaccination. Vaccine. 2024. PMID: 39033078. doi:10.1016/j.vaccine.2024.07.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。